decreases insulin resistance so that the dosage of insulin used by diabetics can be reduced. Octreotide
appears to have no benefits in those with intact insulin reserves (type 2 diabetes). In addition, octreotide
has been reported to reduce sulphonylurea-induced hypoglycaemia.
is used, anticipate the need to reduce the insulin dosage (studies suggest by up to 50%). Octreotide
may affect insulin secretion, and therefore glucose tolerance, and so it would certainly be prudent to monitor the effects of giving octreotide
with any of the oral antidiabetics